Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MED
MED logo

MED Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
12.760
Open
12.510
VWAP
12.43
Vol
182.99K
Mkt Cap
139.99M
Low
12.130
Amount
2.27M
EV/EBITDA(TTM)
--
Total Shares
11.12M
EV
-28.96M
EV/OCF(TTM)
-7.79
P/S(TTM)
0.40
Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.
Show More

Events Timeline

(ET)
2026-05-04
16:20:00
Sees Q2 Revenue of $60M-$80M, Estimate at $74.7M
select
2026-05-04
16:20:00
Sees FY26 Revenue of $270M to $300M
select
2026-05-04
16:10:00
Medifast Q1 Revenue of $76.0M Beats Estimates
select
2026-03-20 (ET)
2026-03-20
08:40:00
Medifast Nominates Independent Director Candidates
select
2026-02-17 (ET)
2026-02-17
16:21:00
Sees FY26 Revenue of $270M-$300M
select
2026-02-17
16:10:00
Sees Q1 Revenue of $65M to $80M
select
2026-02-17
16:10:00
Medifast Q4 Revenue $75.1M, Down from $119.003M Last Year
select

News

seekingalpha
9.5
05-05seekingalpha
Medifast Q1 Earnings Beat Expectations, Shares Surge 18%
  • Significant Stock Surge: Medifast shares jumped nearly 18% on Tuesday, rising from $10.63 to approximately $12.63, significantly outperforming the S&P 500's 15.13% one-day gain, reflecting market optimism about the company's future potential.
  • Weak Financial Performance: Despite Q1 revenue falling 34.3% year-over-year to $76 million, primarily due to a 44.9% drop in active coaches to 14,000, the average revenue per active coach increased by 19.2% to $5,432, indicating improved productivity among the remaining coaches.
  • Effective Cost Control: The company's gross profit declined 38.6% to $51.8 million in Q1, yet SG&A expenses fell by 35.6%, demonstrating the effectiveness of its cost-cutting measures, with expectations of generating over $30 million in future savings.
  • Positive Future Outlook: Although the net loss widened to $2.1 million (or $0.19 per share), the company ended the quarter with $168.9 million in cash and no debt, with management stating that they have realigned their cost structure effectively and plan to launch a new metabolic health system in July, which could further fuel stock price increases.
seekingalpha
9.5
05-04seekingalpha
Medifast Q1 2026 Earnings Call Insights and Outlook
  • Initial Revenue Growth: Medifast reported Q1 2026 revenue of $76 million, a 34.3% year-over-year decline, yet marked the first sequential revenue growth in three years, indicating early signs of business stabilization that could lay the groundwork for future market recovery.
  • Declining Coach Numbers: The number of active earning coaches fell to approximately 14,000, down 44.9% year-over-year; however, the average revenue per coach increased by 19.2% to $5,432, suggesting progress in enhancing coach productivity despite the overall decline.
  • Cost Structure Optimization: The company anticipates generating over $30 million in future savings through a realignment of its cost structure, which not only helps address market realities but may also facilitate a return to profitability starting in Q4 2026, thereby strengthening financial health.
  • New Product Line Launch: Medifast plans to unveil a new comprehensive metabolic system at its coach convention in July, with management reiterating that this product launch will be crucial for restoring profitability, expected to drive sustained earnings growth into 2027 and beyond.
seekingalpha
9.5
05-03seekingalpha
Medifast (MED) to Announce Q1 Earnings on May 4th
  • Earnings Announcement Schedule: Medifast (MED) is set to release its Q1 2023 earnings report on May 4th after market close, with consensus EPS estimate at -$0.52 and revenue estimate at $69.2 million, reflecting a 40.2% year-over-year decline.
  • Historical Performance: Over the past two years, Medifast has exceeded EPS estimates 88% of the time and revenue estimates 88% of the time, indicating a degree of stability in its financial performance despite current challenges.
  • Expectation Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and one downward revision, suggesting market caution regarding future performance.
  • Future Revenue Targets: Medifast has outlined a revenue target of $270 million to $300 million for 2026, indicating the company's commitment to driving execution amid CEO transition and a focus on metabolic health for long-term growth.
Yahoo Finance
9.5
05-03Yahoo Finance
Medifast Earnings Preview: Revenue Expectations Decline
  • Revenue Decline: Medifast reported $75.1 million in revenue last quarter, a 36.9% year-over-year drop, with full-year revenue and EPS guidance significantly missing analysts' expectations, indicating ongoing market challenges for the company.
  • Market Expectations: This quarter, the market anticipates a 40.2% year-over-year revenue decline for Medifast, a further deceleration from the 33.8% decrease recorded in the same quarter last year, reflecting a trend of weakening consumer demand.
  • Analyst Confidence: Despite Medifast missing Wall Street's revenue estimates multiple times over the past two years, analysts covering the company have reaffirmed their estimates in the last 30 days, suggesting a cautiously optimistic outlook for the company's future performance.
  • Competitive Comparison: In the consumer staples sector, Estée Lauder and Vita Coco reported year-over-year growth of 4.6% and 37.3%, respectively, highlighting strong performances from industry peers and increasing pressure on Medifast to improve its results.
NASDAQ.COM
5.0
03-30NASDAQ.COM
Insider Buying at Cardinal Infrastructure and Medifast
  • CDNL Insider Purchase: Ivy Zelman, a director at Cardinal Infrastructure Group, bought 6,921 shares of CDNL at $36.33 each, totaling $251,440, with a current gain of about 6.9%, indicating strong market confidence.
  • Stock Performance: CDNL is up approximately 4.2% on Monday, reflecting investor optimism about the company's prospects, with Zelman's purchase further bolstering market sentiment.
  • MED Insider Purchase: Medifast CEO Daniel R. Chard purchased 17,678 shares at $10.11 each on Wednesday, totaling $178,725, demonstrating management's confidence in the company's future.
  • Historical Trading Comparison: Chard previously bought 5,003 shares at $13.13 each over the past year, indicating a sustained investment commitment to Medifast despite the current stock price decline.
Newsfilter
5.0
03-20Newsfilter
Medifast Nominates New Director Candidates for 2026 Meeting
  • Board Nominations: Medifast has announced the nomination of Parsa Kiai and Jeff Rose as independent director candidates for the 2026 Annual Meeting, reflecting a Cooperation Agreement with Steamboat Capital, which owns over 5% of the company's shares, aimed at enhancing board independence and expertise.
  • Management Changes: The Board has decided that Jeffrey Brown and Michael Hoer will not seek reelection, with current CEO Dan Chard set to step down on June 1, 2026, and Nicholas Johnson expected to succeed him, indicating a strategic shift in leadership to align with future growth.
  • Strategic Cooperation Agreement: Under the Cooperation Agreement with Steamboat Capital, both parties have agreed to certain voting and standstill provisions until the 2027 Annual Meeting, aiming to drive Medifast's continued development and profitability, thereby enhancing shareholder returns.
  • Market Potential Recognition: Parsa Kiai, Managing Partner at Steamboat Capital, noted that the market significantly undervalues Medifast's financial and intrinsic assets, emphasizing the company's unique platform in metabolic health and its long-term growth potential, suggesting that future collaboration will drive sustainable profitability.

Valuation Metrics

The current forward P/E ratio for Medifast Inc (MED.N) is 12.48, compared to its 5-year average forward P/E of 10.71. For a more detailed relative valuation and DCF analysis to assess Medifast Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
10.71
Current PE
12.48
Overvalued PE
76.72
Undervalued PE
-55.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.23
Current EV/EBITDA
-21.07
Overvalued EV/EBITDA
10.30
Undervalued EV/EBITDA
2.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.85
Current PS
0.55
Overvalued PS
1.35
Undervalued PS
0.36

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

surging stocks between 10 to $20
Intellectia · 547 candidates
Price: $10.00 - $20.00Moving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
FSEA logo
FSEA
First Seacoast Bancorp Inc
78.21M
VRDN logo
VRDN
Viridian Therapeutics Inc
1.93B
BDSX logo
BDSX
Biodesix Inc
151.02M
AIOS logo
AIOS
AIOS Tech Inc
63.69M
ONEG logo
ONEG
OneConstruction Group Ltd
175.36M
IART logo
IART
Integra Lifesciences Holdings Corp
1.03B
rerun right now to see if the list changes
Intellectia · 29 candidates
Price: $3.00 - $100.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 60One Day Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SIDU logo
SIDU
Sidus Space Inc
234.80M
DBGI logo
DBGI
Digital Brands Group Inc (Pre-Reincorporation)
68.45M
MED logo
MED
Medifast Inc
128.60M
AAP logo
AAP
Advance Auto Parts Inc
2.75B
CMBT logo
CMBT
CMB.TECH NV
3.30B
LSTA logo
LSTA
Lisata Therapeutics Inc
35.81M

Whales Holding MED

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Medifast Inc (MED) stock price today?

The current price of MED is 12.4 USD — it has decreased -1.51

What is Medifast Inc (MED)'s business?

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.

What is the price predicton of MED Stock?

Wall Street analysts forecast MED stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MED is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Medifast Inc (MED)'s revenue for the last quarter?

Medifast Inc revenue for the last quarter amounts to 76.04M USD, decreased -34.29

What is Medifast Inc (MED)'s earnings per share (EPS) for the last quarter?

Medifast Inc. EPS for the last quarter amounts to -0.19 USD, increased 171.43

How many employees does Medifast Inc (MED). have?

Medifast Inc (MED) has 380 emplpoyees as of May 11 2026.

What is Medifast Inc (MED) market cap?

Today MED has the market capitalization of 139.99M USD.